Soft tissue sarcomas in the first year of life

Sultan, Iyad; Casanova, Michela; Al-Jumaily, Usama; Meazza, Cristina; Rodríguez‐Galindo, Carlos; Ferrari, Andrea

doi:10.1016/j.ejca.2010.05.002

Cited by 66 publications

(50 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infantile fibrosarcoma (IFS) is the most common non-rhabdomyosarcoma soft tissue tumor with an incidence of 24.5 % of all soft tissue sarcomas seen in the first year of life [2]. It can be present at birth or can develop during the first 5 years, particularly in infants and toddlers younger than 2 years; 80 % of cases are diagnosed during the first year of life [3–5].…”

Section: Introductionmentioning

confidence: 99%

Clinical management of infantile fibrosarcoma: a retrospective single-institution review

et al. 2013

View full text Add to dashboard Cite

Background Infantile fibrosarcoma (IFS) is an uncommon soft-tissue sarcoma. Here we review our experience treating this tumor. Patients and methods We retrospectively reviewed records of patients with IFS treated at St. Jude Children’s Research Hospital between 1980 and 2009. Results We identified 15 patients, 8 girls and 7 boys; 13 white and 2 black. Median age at diagnosis was 3 months. Primary sites included the leg (n = 3), chest wall (n = 2), foot (n = 2), and one each in the tongue, occipital region, axilla, parascapular region, arm, forearm, retroperitoneum, and thigh. All patients underwent resection; 11 upfront surgery, and 4 delayed. Complications included loss of the posterior tibial nerve and artery, axillary vein, biceps, pectoralis major, gallbladder, and transverse/sigmoid sinus. Eight received chemotherapy and three radiotherapy. Seven experienced local recurrence and three lung metastasis. Median follow-up was 65 months. At the time of the review, 12 patients were alive and 3 had died. All deaths were in patients older than 1 year at diagnosis with an axial primary site. Conclusions Non-mutilating surgery should be the primary treatment for IFS. Neoadjuvant chemotherapy is indicated when upfront resection is unfeasible. Patients with positive surgical margins should receive adjuvant chemotherapy. Radiotherapy is indicated for axial primary sites where complete resection is impossible.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical management of infantile fibrosarcoma: a retrospective single-institution review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Infantile fibrosarcoma is one of the most common non‐rhabdomyosarcoma soft‐tissue sarcomas in childhood, accounting for 25% of all sarcomas in children younger than 1 year of age . Most patients with IFS present with a tumor in the extremities, followed by trunk, head and neck, and rarely the pelvis, while metastatic disease is seen in 8% of cases . The disease has a good prognosis, with an overall survival rate of 89–94% …”

Section: Discussionmentioning

confidence: 99%

“…1 Most patients with IFS present with a tumor in the extremities, followed by trunk, head and neck, and rarely the pelvis, while metastatic disease is seen in 8% of cases. 1 The disease has a good prognosis, with an overall survival rate of 89-94%. 1…”

Section: Discussionmentioning

confidence: 99%

“…Infantile fibrosarcoma (IFS) is one of the most common non‐rhabdomyosarcoma soft‐tissue sarcomas occurring in children aged <1 year, with an overall survival rate of 89–94%; and minimization of the use of toxic agents is therefore the current challenge. Recent studies of IFS avoided the use of alkylating agents or anthracycline and showed that a vincristine and dactinomycin (VA) regimen appeared to be very effective in IFS .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

Yoshihara

Yoshimoto

Hosoya

et al. 2017

Pediatrics International

View full text Add to dashboard Cite

Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

show abstract

“…Rhabdomyosarcoma represents approximately one‐third of all STS in infants, followed by fibrosarcoma and malignant rhabdoid tumor. Synovial sarcoma was observed in 239 of 3,316 patients 1–18 years of age but in none of 302 infants with STS . As such, determining the appropriate therapeutic strategies for early infantile synovial sarcoma can be difficult.…”

mentioning

confidence: 99%